Table 8.
Change in CD4+ cell count from baseline to week 24 and number (%) of participants with CD4+ cell count increases
| All Participants (N = 734) | Treatment-Naïve (N = 140) | PI-Naïve but Treatment- Experienced (N = 90) | Toxicity Switch from Other PI Regimen (N = 62) | Toxicity Switch from Prior Non-PI Regimen (N = 85) | HCV Coinfection (N = 57) | Prior PI Regimen (N = 503) | Prior Non-PI Regimen (N = 588) | |
|---|---|---|---|---|---|---|---|---|
| Change in CD4+ cell count from baseline to week 24 | ||||||||
| Median (25th–75th quartile) | 63 | 138 | 116 | 8 | 57 | 57 | 36 | 47 |
| (−19–169) | (63–236) | (22–258) | (−82–67) | (−38–207) | (3–148) | (−34–127) | (−32–139) | |
| Number (%) of participants with increases in CD4+ cell count from baseline to week 24 | ||||||||
| 523 (71.3) | 129 (92.1) | 71 (78.9) | 34 (54.8) | 57 (67.1) | 44 (77.2) | 322 (64.0) | 390 (66.3) | |
HCV = hepatitis C virus; PI = protease inhibitor.